Novartis AG (NVS)

業務介紹

諾華股份有限公司在全球範圍內從事醫療保健產品的研究、開發、製造和銷售。該公司通過兩個業務部門運營,分別是創新藥品部門和仙德士部門。創新藥品部門提供處方藥物給患者和醫療服務提供者。它還提供眼科、神經科學、免疫學、肝病學、皮膚病學、呼吸系統、心血管系統、腎臟和代謝醫學產品。仙德士部門開發、製造和銷售成品藥物;向第三方提供小分子藥物的原料藥和成品劑型;以及零售仿製藥和抗感染藥物。它還提供主要是抗生素的原料藥和中間體;蛋白質或其他生物技術產品,包括生物類似藥;以及生物技術製造服務。諾華股份有限公司與Alnylam Pharmaceuticals簽有許可和合作協議,以開發、製造和商業化inclisiran;並與Kura Oncology, Inc.簽有臨床合作協議,以評估Tipifarnib和Alpelisib在頭頸部鱗狀細胞癌患者中的聯合療效。該公司於1996年註冊成立,總部位於瑞士巴塞爾。



Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

公司網址

https://www.novartis.com